Cholesterol-lowering drugs in the same category as Pfizer Inc.'s Lipitor don’t reduce cancer rates as preliminary research had suggested, according to two large-scale studies published this week in medical journals.
Cholesterol-lowering drugs in the same category as Pfizer Inc.'s Lipitor don’t reduce cancer rates as preliminary research had suggested, according to two large-scale studies published this week in medical journals.
